Nuformix submits NXP002 Orphan Drug Designation draft application

Nuformix plc

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that it has submitted a draft application document in advance of a pre-submission meeting with the European Medicines Agency (EMA) regarding an Orphan Drug Designation (ODD) for the Company’s lead asset NXP002, a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF).  This is the first stage in the process for the Company to potentially secure ODD for NXP002 in IPF.

The pre-submission meeting will occur later in January 2025.  The EMA strongly encourages sponsors to request a pre-submission meeting prior to filing an application, the precise timing of which will depend upon feedback received, but could be before the end of January 2025.  Upon submission of the application the Company will make a further announcement and confirm the anticipated timelines associated with the review and the EMA’s decision on NXP002’s ODD in IPF.

Nuformix is also pleased to confirm that discussions with potential partners to secure an out-licence or option agreement for NXP002 continue to proceed with a number of parties.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges.

Nuformix advances NXP002 as EMA backs Orphan Drug status

Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights.

Nuformix secures positive EMA opinion for orphan drug status in IPF

Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF).

Nuformix updates Registered Office and Company Secretary

Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary.

Nuformix reports positive NXP002 results in lung disease models

Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways.

Nuformix advances NXP002 programme with £168,750 Placing

Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals.

Search

Search